Glaukos (6GJ) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

6GJ Analyst Ratings

Strong Buy

12 Buy

1 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Glaukos

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

6GJ Stock 12 Month Forecast

Average Price Target

€166.06

▲(26.76% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Glaukos in the last 3 months. The average price target is €166.06 with a high forecast of €193.01 and a low forecast of €141.54. The average price target represents a 26.76% change from the last price of €131.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"67":"€67","194":"€194","98.75":"€98.8","130.5":"€130.5","162.25":"€162.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":193.0071375,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€193.01</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":166.057622375,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€166.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":141.5385675,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€141.54</span>\n  </div></div>","useHTML":true}}],"tickPositions":[67,98.75,130.5,162.25,194],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,145,148.69285673076922,152.38571346153847,156.0785701923077,159.77142692307692,163.46428365384617,167.1571403846154,170.8499971153846,174.54285384615383,178.23571057692308,181.9285673076923,185.62142403846156,189.31428076923078,{"y":193.0071375,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,145,146.61981710576924,148.23963421153846,149.8594513173077,151.47926842307692,153.09908552884616,154.71890263461538,156.33871974038462,157.95853684615383,159.57835395192308,161.1981710576923,162.81798816346154,164.43780526923075,{"y":166.057622375,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,145,144.73373596153846,144.4674719230769,144.20120788461537,143.93494384615386,143.6686798076923,143.40241576923077,143.13615173076923,142.86988769230769,142.60362365384614,142.33735961538463,142.07109557692308,141.80483153846154,{"y":141.5385675,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":74,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.5,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.5,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":145,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€193.01

Average Price Target€166.06

Lowest Price Target€141.54

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ryan Zimmerman

BTIG

€165.56→€173.28

Buy

32.27%

Upside

Assigned

08/20/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Joanne Wuensch

Citi

€161.27→€193.01

Buy

47.33%

Upside

Reiterated

08/14/26

Glaukos (GKOS) Gets a Buy from Citi

Adam Maeder

Piper Sandler

€141.54→€167.27

Buy

27.69%

Upside

Reiterated

08/07/26

Glaukos (GKOS) Gets a Buy from Piper Sandler

Allen Gong

J.P. Morgan

€171.56

Buy

30.96%

Upside

Reiterated

08/04/26

Glaukos (GKOS) Gets a Buy from J.P. Morgan

Anthony Petrone

Mizuho Securities

€158.69

Buy

21.14%

Upside

Reiterated

07/31/26

Mizuho Securities Sticks to Their Buy Rating for Glaukos (GKOS)

Steven Lichtman

William Blair

―

Buy

―

Reiterated

07/30/26

Analysts Offer Insights on Healthcare Companies: Adaptive Biotechnologies (NASDAQ: ADPT), Viking Therapeutics (NASDAQ: VKTX) and Glaukos (NYSE: GKOS)

Richard Newitter

Truist Financial

€154.41→€184.43

Buy

40.79%

Upside

Reiterated

07/30/26

Truist Financial Keeps Their Buy Rating on Glaukos (GKOS)

Thomas Stephan

Stifel Nicolaus

€150.12→€162.98

Buy

24.42%

Upside

Reiterated

07/30/26

Stifel Nicolaus Sticks to Their Buy Rating for Glaukos (GKOS)

Larry Biegelsen

Wells Fargo

€118.38→€152.69

Buy

16.56%

Upside

Assigned

07/30/26

Analysts Are Bullish on Top Healthcare Stocks: MannKind (MNKD), Humana (HUM)

Yi Chen

H.C. Wainwright

€144.11→€167.27

Buy

27.69%

Upside

Reiterated

07/30/26

Glaukos price target raised to $195 from $168 at H.C. WainwrightGlaukos price target raised to $195 from $168 at H.C. Wainwright

David Saxon

Needham

€128.67→€172.42

Buy

31.62%

Upside

Reiterated

07/30/26

Analysts Offer Insights on Healthcare Companies: Glaukos (NYSE: GKOS) and MannKind (NASDAQ: MNKD)

Patrick Wood

UBS

€128.67→€147.54

Hold

12.63%

Upside

Reiterated

07/30/26

Glaukos assumed with Neutral from Buy at UBSGlaukos assumed with Neutral from Buy at UBS

Unknown Analyst

Jefferies

Not Ranked

Jefferies

€141.54

Buy

8.04%

Upside

Reiterated

06/23/26

Jefferies Remains a Buy on Glaukos (GKOS)

David Roman

Goldman Sachs

€131.24

Buy

0.19%

Upside

Reiterated

05/25/26

Goldman Sachs Reaffirms Their Buy Rating on Glaukos (GKOS)

Mason Carrico

Stephens

€98.65→€124.38

Buy

-5.05%

Downside

Reiterated

01/02/26

Glaukos price target raised to $145 from $115 at StephensGlaukos price target raised to $145 from $115 at Stephens

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ryan Zimmerman

BTIG

€165.56→€173.28

Buy

32.27%

Upside

Assigned

08/20/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Joanne Wuensch

Citi

€161.27→€193.01

Buy

47.33%

Upside

Reiterated

08/14/26

Glaukos (GKOS) Gets a Buy from Citi

Adam Maeder

Piper Sandler

€141.54→€167.27

Buy

27.69%

Upside

Reiterated

08/07/26

Glaukos (GKOS) Gets a Buy from Piper Sandler

Allen Gong

J.P. Morgan

€171.56

Buy

30.96%

Upside

Reiterated

08/04/26

Glaukos (GKOS) Gets a Buy from J.P. Morgan

Anthony Petrone

Mizuho Securities

€158.69

Buy

21.14%

Upside

Reiterated

07/31/26

Mizuho Securities Sticks to Their Buy Rating for Glaukos (GKOS)

Steven Lichtman

William Blair

―

Buy

―

Reiterated

07/30/26

Analysts Offer Insights on Healthcare Companies: Adaptive Biotechnologies (NASDAQ: ADPT), Viking Therapeutics (NASDAQ: VKTX) and Glaukos (NYSE: GKOS)

Richard Newitter

Truist Financial

€154.41→€184.43

Buy

40.79%

Upside

Reiterated

07/30/26

Truist Financial Keeps Their Buy Rating on Glaukos (GKOS)

Thomas Stephan

Stifel Nicolaus

€150.12→€162.98

Buy

24.42%

Upside

Reiterated

07/30/26

Stifel Nicolaus Sticks to Their Buy Rating for Glaukos (GKOS)

Larry Biegelsen

Wells Fargo

€118.38→€152.69

Buy

16.56%

Upside

Assigned

07/30/26

Analysts Are Bullish on Top Healthcare Stocks: MannKind (MNKD), Humana (HUM)

Yi Chen

H.C. Wainwright

€144.11→€167.27

Buy

27.69%

Upside

Reiterated

07/30/26

Glaukos price target raised to $195 from $168 at H.C. WainwrightGlaukos price target raised to $195 from $168 at H.C. Wainwright

David Saxon

Needham

€128.67→€172.42

Buy

31.62%

Upside

Reiterated

07/30/26

Analysts Offer Insights on Healthcare Companies: Glaukos (NYSE: GKOS) and MannKind (NASDAQ: MNKD)

Patrick Wood

UBS

€128.67→€147.54

Hold

12.63%

Upside

Reiterated

07/30/26

Glaukos assumed with Neutral from Buy at UBSGlaukos assumed with Neutral from Buy at UBS

Unknown Analyst

Jefferies

Not Ranked

Jefferies

€141.54

Buy

8.04%

Upside

Reiterated

06/23/26

Jefferies Remains a Buy on Glaukos (GKOS)

David Roman

Goldman Sachs

€131.24

Buy

0.19%

Upside

Reiterated

05/25/26

Goldman Sachs Reaffirms Their Buy Rating on Glaukos (GKOS)

Mason Carrico

Stephens

€98.65→€124.38

Buy

-5.05%

Downside

Reiterated

01/02/26

Glaukos price target raised to $145 from $115 at StephensGlaukos price target raised to $145 from $115 at Stephens

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ODTXOdyssey Therapeutics, Inc.

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

GPCRStructure Therapeutics, Inc. Sponsored ADR

AMLXAmylyx Pharmaceuticals Inc

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Glaukos

3 Months

Adam MaederPiper Sandler

Success Rate

13/14 ratings generated profit

Average Return

+17.96%

Copying Adam Maeder's trades and holding each position for 3 Months would result in 92.86% of your transactions generating a profit, with an average return of +17.96% per trade.

1 Year

Adam MaederPiper Sandler

Success Rate

14/14 ratings generated profit

Average Return

+64.41%

Copying Adam Maeder's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +64.41% per trade.

2 Years

Adam MaederPiper Sandler

Success Rate

14/14 ratings generated profit

Average Return

+73.55%

Copying Adam Maeder's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +73.55% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

6GJ Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 6GJ has received 32 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 6GJ average Analyst price target in the past 3 months is 166.06.

Each month's total comprises the sum of three months' worth of ratings.

6GJ Financial Forecast

6GJ Earnings Forecast

Next quarter’s earnings estimate for 6GJ is -€0.08 with a range of -€0.15 to -€0.03. The previous quarter’s EPS was -€0.12. 6GJ beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 6GJ has Performed in-line its overall industry.

6GJ Sales Forecast

Next quarter’s sales forecast for 6GJ is €143.80M with a range of €137.12M to €148.99M. The previous quarter’s sales results were €158.94M. 6GJ beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 6GJ has Performed in-line its overall industry.

6GJ Stock Forecast FAQ

What is DE:6GJ’s average 12-month price target, according to analysts?

Based on analyst ratings, Glaukos’s 12-month average price target is 166.06.

What is DE:6GJ’s upside potential, based on the analysts’ average price target?

Glaukos has 26.76% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Glaukos a Buy, Sell or Hold?

Glaukos has a consensus rating of Strong Buy, which is based on 12 buy ratings, 1 hold ratings and 0 sell ratings.

What is Glaukos’s share price target?

The average share price target for Glaukos is 166.06. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €193.01 ,and the lowest forecast is €141.54. The average share price target represents 26.76% Increase from the current price of €131.

What do analysts say about Glaukos?

Glaukos’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of Glaukos?

To buy shares of DE:6GJ, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Glaukos (6GJ) Stock Forecast & Price Target

6GJ Analyst Ratings

6GJ Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Glaukos

6GJ Analyst Recommendation Trends

6GJ Financial Forecast

6GJ Earnings Forecast

6GJ Sales Forecast

6GJ Stock Forecast FAQ

Detailed List of Analyst Forecasts